Selected research
Industry Research
SARS-Cov-2 Vaccine (Vero Cell) Industry Research Report 2026
Market perspective
The global SARS-Cov-2 Vaccine (Vero Cell) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for SARS-Cov-2 Vaccine (Vero Cell) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for SARS-Cov-2 Vaccine (Vero Cell) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for SARS-Cov-2 Vaccine (Vero Cell) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of SARS-Cov-2 Vaccine (Vero Cell) include Sinopharm, Pfizer, WIBP, Sinovac Biotech, IMBCAMS,China and BIBP, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global SARS-Cov-2 Vaccine (Vero Cell) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
SARS-Cov-2 Vaccine (Vero Cell) Market by Company
Sinopharm
Pfizer
WIBP
Sinovac Biotech
IMBCAMS,China
BIBP
SARS-Cov-2 Vaccine (Vero Cell) Segment by Type
Subunit Vaccine
Whole Virus Inactivated Vaccine
Split Vaccine
Others
SARS-Cov-2 Vaccine (Vero Cell) Segment by Application
Special Population
General Population
SARS-Cov-2 Vaccine (Vero Cell) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-Cov-2 Vaccine (Vero Cell) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SARS-Cov-2 Vaccine (Vero Cell) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-Cov-2 Vaccine (Vero Cell).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of SARS-Cov-2 Vaccine (Vero Cell) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of SARS-Cov-2 Vaccine (Vero Cell) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of SARS-Cov-2 Vaccine (Vero Cell) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Subunit Vaccine
- Whole Virus Inactivated Vaccine
- Split Vaccine
- Others
Applications
- Special Population
- General Population
Companies covered
- Sinopharm
- Pfizer
- WIBP
- Sinovac Biotech
- IMBCAMS,China
- BIBP
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Market Size (2021-2032)
- 2.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales (2021-2032)
- 2.2.3 Global SARS-Cov-2 Vaccine (Vero Cell) Market Average Price (2021-2032)
- 2.3 SARS-Cov-2 Vaccine (Vero Cell) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Subunit Vaccine
- 2.3.3 Whole Virus Inactivated Vaccine
- 2.3.4 Split Vaccine
- 2.3.5 Others
- 2.4 SARS-Cov-2 Vaccine (Vero Cell) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Special Population
- 2.4.3 General Population
3 Market Competitive Landscape by Manufacturers
- 3.1 Global SARS-Cov-2 Vaccine (Vero Cell) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue of Manufacturers (2021-2026)
- 3.4 Global SARS-Cov-2 Vaccine (Vero Cell) Average Price by Manufacturers (2021-2026)
- 3.5 Global SARS-Cov-2 Vaccine (Vero Cell) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of SARS-Cov-2 Vaccine (Vero Cell), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of SARS-Cov-2 Vaccine (Vero Cell), Product Type & Application
- 3.8 Global Manufacturers of SARS-Cov-2 Vaccine (Vero Cell), Established Date
- 3.9 Global SARS-Cov-2 Vaccine (Vero Cell) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sinopharm
- 4.1.1 Sinopharm Company Information
- 4.1.2 Sinopharm Business Overview
- 4.1.3 Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.1.5 Sinopharm Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 WIBP
- 4.3.1 WIBP Company Information
- 4.3.2 WIBP Business Overview
- 4.3.3 WIBP SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 WIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.3.5 WIBP Recent Developments
- 4.4 Sinovac Biotech
- 4.4.1 Sinovac Biotech Company Information
- 4.4.2 Sinovac Biotech Business Overview
- 4.4.3 Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.4.5 Sinovac Biotech Recent Developments
- 4.5 IMBCAMS,China
- 4.5.1 IMBCAMS,China Company Information
- 4.5.2 IMBCAMS,China Business Overview
- 4.5.3 IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.5.5 IMBCAMS,China Recent Developments
- 4.6 BIBP
- 4.6.1 BIBP Company Information
- 4.6.2 BIBP Business Overview
- 4.6.3 BIBP SARS-Cov-2 Vaccine (Vero Cell) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 BIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
- 4.6.5 BIBP Recent Developments
5 Global SARS-Cov-2 Vaccine (Vero Cell) Market Scenario by Region
- 5.1 Global SARS-Cov-2 Vaccine (Vero Cell) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region: 2021-2032
- 5.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region: 2021-2026
- 5.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region: 2027-2032
- 5.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region: 2021-2032
- 5.3.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region: 2021-2026
- 5.3.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region: 2027-2032
- 5.4 North America SARS-Cov-2 Vaccine (Vero Cell) Market Facts & Figures by Country
- 5.4.1 North America SARS-Cov-2 Vaccine (Vero Cell) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
- 5.4.3 North America SARS-Cov-2 Vaccine (Vero Cell) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe SARS-Cov-2 Vaccine (Vero Cell) Market Facts & Figures by Country
- 5.5.1 Europe SARS-Cov-2 Vaccine (Vero Cell) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
- 5.5.3 Europe SARS-Cov-2 Vaccine (Vero Cell) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Market Facts & Figures by Country
- 5.6.1 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America SARS-Cov-2 Vaccine (Vero Cell) Market Facts & Figures by Country
- 5.7.1 South America SARS-Cov-2 Vaccine (Vero Cell) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
- 5.7.3 South America SARS-Cov-2 Vaccine (Vero Cell) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021-2032)
- 6.1.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Type (2021-2032)
- 6.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2021-2032)
- 6.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Type (2021-2032)
- 6.3 Global SARS-Cov-2 Vaccine (Vero Cell) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021-2032)
- 7.1.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Application (2021-2032)
- 7.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2021-2032)
- 7.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Application (2021-2032)
- 7.3 Global SARS-Cov-2 Vaccine (Vero Cell) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 SARS-Cov-2 Vaccine (Vero Cell) Value Chain Analysis
- 8.1.1 SARS-Cov-2 Vaccine (Vero Cell) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 SARS-Cov-2 Vaccine (Vero Cell) Production Mode & Process
- 8.2 SARS-Cov-2 Vaccine (Vero Cell) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 SARS-Cov-2 Vaccine (Vero Cell) Distributors
- 8.2.3 SARS-Cov-2 Vaccine (Vero Cell) Customers
9 Global SARS-Cov-2 Vaccine (Vero Cell) Analyzing Market Dynamics
- 9.1 SARS-Cov-2 Vaccine (Vero Cell) Industry Trends
- 9.2 SARS-Cov-2 Vaccine (Vero Cell) Industry Drivers
- 9.3 SARS-Cov-2 Vaccine (Vero Cell) Industry Opportunities and Challenges
- 9.4 SARS-Cov-2 Vaccine (Vero Cell) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst